SAFETY DATA SHEET

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Palbociclib Capsules

Trade Name: IBRANCE
Compound Number: PD 0332991; PF-00080665
Chemical Family: Not determined

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product

Details of the Supplier of the Safety Data Sheet

Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017
1-800-879-3477

Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: pfizer-MSDS@pfizer.com

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification

Germ Cell Mutagenicity: Category 2
Specific target organ systemic toxicity (repeated exposure): Category 2

EU Classification:

EU Indication of danger: Xn - Harmful
Mutagenic: Category 3

EU Risk Phrases:

R68 - Possible risk of irreversible effects.
R48/22 - Harmful: danger of serious damage to health by prolonged exposure if swallowed.

Label Elements

Signal Word: Warning

Hazard Statements:

H341 - Suspected of causing genetic defects
H373 - May cause damage to organs through prolonged or repeated exposure: testes, bone marrow

Precautionary Statements:

P201 - Obtain special instructions before use
P260 - Do not breathe dust/fume/gas/mist/vapors/spray
P281 - Use personal protective equipment as required
P308 + P313 - IF exposed or concerned: Get medical attention/advice
P314 - Get medical attention/advice if you feel unwell
P405 - Store locked up
Other Hazards

Note: This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>EU Classification</th>
<th>GHS Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Palbociclib (PD 0332991)</td>
<td>571190-30-2</td>
<td>Not Listed</td>
<td>Xn; R48/22</td>
<td>Muta 2 (H341)</td>
<td>20 - 30</td>
</tr>
<tr>
<td>Cellulose microcrystalline</td>
<td>9004-34-4</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Colloidal silicon dioxide</td>
<td>7631-86-9</td>
<td>231-545-4</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Lactose Monohydrate</td>
<td>64044-51-5</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Magnesium Stearate</td>
<td>557-04-0</td>
<td>209-150-3</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Sodium starch glycolate</td>
<td>9063-38-1</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
</tbody>
</table>

Additional Information: * Proprietary
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the R phrases and CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.
Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed
Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.
Medical Conditions Aggravated by Exposure: None known

Indication of the Immediate Medical Attention and Special Treatment Needed
Notes to Physician: None

5. FIRE FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO2, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture
Hazardous Combustion: Formation of toxic gases is possible during heating or fire.
Products: Fine particles (such as dust and mists) may fuel fires/explosions.

Advice for Fire-Fighters
During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures
Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions
Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up
Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling
Minimize dust generation and accumulation. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities
Storage Conditions: Store as directed by product packaging.
Specific end use(s): Pharmaceutical product

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters
8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Refer to available public information for specific member state Occupational Exposure Limits.

Palbociclib (PD 0332991)

Pfizer OEL TWA-8 Hr: 1µg/m³

Colloidal silicon dioxide

Australia TWA 2 mg/m³
Austria OEL - MAKs 4 mg/m³
Czech Republic OEL - TWA 0.1 mg/m³
Estonia OEL - TWA 2 mg/m³
Finland OEL - TWA 5 mg/m³
Germany - TRGS 900 - TWAs 4 mg/m³
Germany (DFG) - MAK 4 mg/m³
Ireland OEL - TWAs 6 mg/m³
Latvia OEL - TWA 1 mg/m³
OSHA - Final PELs - Table Z-3 Mineral D: 20 mppcf Listed
Slovakia OEL - TWA 4.0 mg/m³
Switzerland OEL -TWAs 4 mg/m³

Magnesium Stearate

ACGIH Threshold Limit Value (TWA) 10 mg/m³
Lithuania OEL - TWA 5 mg/m³
Sweden OEL - TWA 5 mg/m³

Exposure Controls

Engineering Controls: Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Personal Protective Equipment: Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

Hands: Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.

Eyes: Wear safety glasses or goggles if eye contact is possible.

Skin: Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.

Respiratory protection: If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Capsule
Odor: No data available.
Molecular Formula: Mixture

Solvent Solubility: No data available
Water Solubility: No data available
pH: No data available.
Melting/Freezing Point (°C): No data available
9. PHYSICAL AND CHEMICAL PROPERTIES

Boiling Point (°C): No data available.
Partition Coefficient: (Method, pH, Endpoint, Value)
PD 0332991-0054
No data available
Palbociclib (PD 0332991)
Predicted 7.4 Log D 0.05
Cellulose microcrystalline
No data available
Colloidal silicon dioxide
No data available
Sodium starch glycolate
No data available
Magnesium Stearate
No data available
Lactose Monohydrate
No data available
PD 0332991-0002
No data available
Decomposition Temperature (°C): No data available.
Evaporation Rate (Gram/s): No data available
Vapor Pressure (kPa): No data available
Vapor Density (g/ml): No data available
Relative Density: No data available
Viscosity: No data available

Flammability:
Autoignition Temperature (Solid) (°C): No data available
Flammability (Solids): No data available
Flash Point (Liquid) (°C): No data available
Upper Explosive Limits (Liquid) (% by Vol.): No data available
Lower Explosive Limits (Liquid) (% by Vol.): No data available

10. STABILITY AND REACTIVITY

Reactivity: No data available
Chemical Stability: Stable under normal conditions of use.
Possibility of Hazardous Reactions
Oxidizing Properties: No data available
Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions. As a precautionary measure, keep away from heat sources and electrostatic discharge.
Incompatible Materials: As a precautionary measure, keep away from strong oxidizers
Hazardous Decomposition Products: No data available

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects
General Information: Toxicological properties have not been thoroughly investigated. The information included in this section describes the potential hazards of various forms of the active ingredient.
Known Clinical Effects: Based on clinical trials in humans, possible adverse effects following exposure to this compound may include: decreased white blood cells (leukopenia), neutropenia, decreased red blood cell count (anemia), fatigue, and nausea.
11. TOXICOLOGICAL INFORMATION

Acute Toxicity: (Species, Route, End Point, Dose)

**PD 0332991-0054**
Rat Oral Maximally Tolerated Dose 500 mg/kg

**Palbociclib (PD 0332991)**
Rat (M) Oral Minimum Lethal Dose >/= 1000 mg/kg

**Lactose Monohydrate**
Rat Oral LD 50 29700 mg/kg

**PD 0332991-0002**
Dog Oral Maximum Asymptomatic Dose 10 mg/kg

Safety Pharmacology:

**PD 0332991-0054**: Neurofunctional not significant Pulmonary decreased respiratory rate (5.0 mg/kg)

**PD 0332991-0002**: *In vitro* Cardiovascular and *In vivo* Cardiovascular increased QT interval

Irritation / Sensitization: (Study Type, Species, Severity)

**Palbociclib (PD 0332991)**

Eye Irritation (*In vitro*, BCOP) Not applicable Negative

Eye Irritation Rabbit Mild

Skin Irritation Rabbit Non-irritating

Skin Sensitization - LLNA Mouse Negative

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

**PD 0332991-0054**
3 Week(s) Rat Oral 50 mg/kg/day LOAEL Blood, Bone marrow, Lymphoid tissue, Male reproductive system

3 Week(s) Dog Oral 0.2 mg/kg/day NOAEL Blood, Bone Marrow, Lymphoid tissue, Male reproductive system

**Palbociclib (PD 0332991)**

15 Week(s) Rat Oral (M) 10 / (F) 200 mg/kg/day NOAEL Male reproductive system

15 Week(s) Dog Oral (M) 0.2 / (F) 2.0 mg/kg/day NOAEL Male reproductive system

**Magnesium Stearate**

13 Week(s) Rat Oral 1092 g/kg LOAEL Liver

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

**Palbociclib (PD 0332991)**

Embryo / Fetal Development Rabbit Oral 10 mg/kg/day NOAEL Maternal toxicity, Developmental toxicity

Embryo / Fetal Development Rat Oral 100 mg/kg/day NOAEL Maternal Toxicity, Developmental toxicity

Fertility & Early Embryonic Development-Females Rat Oral 300 mg/kg/day NOAEL Reproductive toxicity

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

**PD 0332991-0054**

Bacterial Mutagenicity (Ames) *Salmonella* , *E. coli* Negative

*In Vitro* Cytogenetics Human Lymphocytes Negative

*In Vivo* Micronucleus Rat Bone Marrow Positive

PZ02407
11. TOXICOLOGICAL INFORMATION

Palbociclib (PD 0332991)
Bacterial Mutagenicity (Ames)  Salmonella, E. coli  Negative
In Vitro Chromosome Aberration  Rat Bone Marrow  Positive
In Vitro Kinetochore Analysis  Chinese Hamster Ovary (CHO) cells  Positive

Lactose Monohydrate
In Vitro Bacterial Mutagenicity (Ames)  Negative

PD 0332991-0002
In Vitro Micronucleus  Chinese Hamster Ovary (CHO) cells  Positive without activation
Bacterial Mutagenicity (Biolum Ames)  Salmonella  Negative

Genetic Toxicity Comments:
PD 0332991-0002  The above genetic toxicity studies (In vitro Micronucleus and Biolum Ames) were preliminary assays.
PD 0332991-0054: Investigation into the mechanism of the positive response in the in vivo micronucleus assay suggests an aneugenic rather than clastogenic mechanism.

Carcinogen Status:
None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA. See below

Colloidal silicon dioxide
IARC:
Group 3 (Not Classifiable)

12. ECOLOGICAL INFORMATION

Environmental Overview:
Releases to the environment should be avoided. Environmental properties have not been thoroughly investigated.

Toxicity:
No data available

Persistence and Degradability:
No data available

Bio-accumulative Potential:
Partition Coefficient: (Method, pH, Endpoint, Value)
Palbociclib (PD 0332991)
Predicted 7.4  Log D 0.05

Mobility in Soil:
No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods:
Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.
SAFETY DATA SHEET

Material Name: Palbociclib Capsules
Revision date: 16-Oct-2014

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture
Caution - Substance not fully tested (VIIA)

Canada - WHMIS: Classifications

<table>
<thead>
<tr>
<th>WHMIS hazard class:</th>
<th>D1b  toxic materials</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>D2a  very toxic materials</td>
</tr>
<tr>
<td></td>
<td>D2b  toxic materials</td>
</tr>
</tbody>
</table>

Palbociclib (PD 0332991)

<table>
<thead>
<tr>
<th>CERCLA/SARA 313 Emission reporting</th>
<th>Not Listed</th>
</tr>
</thead>
<tbody>
<tr>
<td>California Proposition 65</td>
<td>Not Listed</td>
</tr>
<tr>
<td>EU EINECS/ELINCS List</td>
<td>Not Listed</td>
</tr>
</tbody>
</table>

Cellulose microcrystalline

<table>
<thead>
<tr>
<th>CERCLA/SARA 313 Emission reporting</th>
<th>Not Listed</th>
</tr>
</thead>
<tbody>
<tr>
<td>California Proposition 65</td>
<td>Not Listed</td>
</tr>
<tr>
<td>EU EINECS/ELINCS List</td>
<td>Not Listed</td>
</tr>
</tbody>
</table>

Colloidal silicon dioxide

<table>
<thead>
<tr>
<th>CERCLA/SARA 313 Emission reporting</th>
<th>Not Listed</th>
</tr>
</thead>
<tbody>
<tr>
<td>California Proposition 65</td>
<td>Not Listed</td>
</tr>
<tr>
<td>Inventory - United States TSCA - Sect. 8(b)</td>
<td>Present</td>
</tr>
<tr>
<td>Australia (AICS):</td>
<td>Present</td>
</tr>
<tr>
<td>EU EINECS/ELINCS List</td>
<td>231-545-4</td>
</tr>
</tbody>
</table>

Lactose Monohydrate

<table>
<thead>
<tr>
<th>CERCLA/SARA 313 Emission reporting</th>
<th>Not Listed</th>
</tr>
</thead>
<tbody>
<tr>
<td>California Proposition 65</td>
<td>Not Listed</td>
</tr>
<tr>
<td>Australia (AICS):</td>
<td>Present</td>
</tr>
<tr>
<td>REACH - Annex IV - Exemptions from the obligations of Register:</td>
<td>Present</td>
</tr>
</tbody>
</table>
### 15. REGULATORY INFORMATION

<table>
<thead>
<tr>
<th>Substance/Ingredient</th>
<th>EU EINECS/ELINCS List</th>
<th>CERCLA/SARA 313 Emission reporting</th>
<th>California Proposition 65</th>
<th>Inventory - United States TSCA - Sect. 8(b)</th>
<th>Australia (AICS):</th>
<th>Inventory - United States TSCA - Sect. 8(b)</th>
<th>Australia (AICS):</th>
<th>EU EINECS/ELINCS List</th>
</tr>
</thead>
<tbody>
<tr>
<td>Magnesium Stearate</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>Present</td>
<td>Present</td>
<td>209-150-3</td>
<td>209-150-3</td>
<td>Not Listed</td>
</tr>
<tr>
<td>Sodium starch glycolate</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>Present</td>
<td>Present</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>Not Listed</td>
</tr>
</tbody>
</table>

### 16. OTHER INFORMATION

**Text of R phrases and GHS Classification abbreviations mentioned in Section 3**

Specific target organ toxicity, repeated exposure-Cat.2; H373 - May cause damage to organs through prolonged or repeated exposure
Germ cell mutagenicity-Cat.2; H341 - Suspected of causing genetic defects

Xn - Harmful
Mutagenic: Category 3
R68 - Possible risks of irreversible effects.
R48/22 - Harmful: danger of serious damage to health by prolonged exposure if swallowed.

**Data Sources:**
Pfizer proprietary drug development information.

**Reasons for Revision:**
Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking. Updated Section 3 - Composition / Information on Ingredients. Updated Section 7 - Handling and Storage. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 11 - Toxicology Information.

**Revision date:**
16-Oct-2014

**Prepared by:**
Product Stewardship Hazard Communication
Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

**End of Safety Data Sheet**